{"prompt": "['2017N330177 0', 'CONFIDENTIAL', 'GlaxoSmithKline group of companies', '205678', 'TITLE PAGE', 'Protocol Title: A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the', 'Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in', 'Participants with Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are', 'Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed', 'an Anti-CD38 Antibody (DREAMM 2)', 'Protocol Number: 205678 Amendment 03', 'Short Title: Open-label, randomized study of two doses of GSK2857916 in participants', 'with relapsed/refractory multiple myeloma who have failed prior treatment with an anti-', 'CD38 antibody', 'Compound Number: GSK2857916', 'Sponsor Name and Legal Registered Address:', 'GlaxoSmithKline Research & Development Limited', '980 Great West Road', 'Brentford', 'Middlesex, TW8 9GS', 'UK', 'Medical Monitor Name and Contact Information: This information will be provided', 'in the Study Reference Manual (SRM).', 'Regulatory Agency Identifying Number(s): IND 119333, EudraCT number 2017-', '004810-25', 'Approval Date: 17-DEC-2018', 'Copyright 2018 The GlaxoSmithKline group of companies. All rights reserved.', 'Unauthorized copying or use of this information is prohibited.', '1']['2017N330177_04', 'CONFIDENTIAL', '-', '205678', 'SPONSOR SIGNATORY', 'Joanna Opalinska, MD', 'Date', 'Director, Clinical Development', '2']['2017N330177_04', 'CONFIDENTIAL', '205678', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', 'DOCUMENT HISTORY', 'Document', 'Date', 'Amendment 3-2017N330177_04', '17-DEC-2018', 'Amendment 2- (Republishing)- 2017N330177_03', '04-SEP-2018', '30-AUG-2018', 'Amendment 2- 2017N330177_02', 'Amendment 1 2017N330177_01', '02-APR-2018', 'Original Protocol-2017N330177_00', '18-Jan-2018', 'Amendment 3: 17-DEC-2018', 'Overall Rationale for the Amendment:', 'The protocol has been amended to address over-enrollment in the frozen liquid solution', 'portion of the study.', 'Due to the over-enrollment, the primary analysis will be based on all randomized', 'participants (anticipated ~200) enrolled into the frozen liquid solution arms. In addition, a', 'sensitivity analysis based on the first 130 participants will be performed to account for', 'the original design.', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'All Sections', 'Removed references of precise number', 'To align with actual enrollment', 'of participants for enrollment', 'Section 2 Schedule of', 'Table 1, footnote 14 Correction of FISH', 'Typographical error', 'Activities', 'testing', 'To allow greater flexibility for', 'Table 2, Footnote 29 and Table 3', 'interview to occur', 'Footnote 19 window added for patient', 'interviews', 'Clarification of ocular assessment', 'Table 4, Footnote 5 clarified', 'timing', 'Section 4 Objectives', 'Addition of Investigator assessed ORR', 'The primary analysis for the', 'and Endpoints', 'as a secondary objective and endpoint.', 'endpoint ORR is based on IRC', 'Section 1 Protocol', 'Removed the specification that clinical', 'assessment. Therefore, a', 'Synopsis Objectives', 'benefit rate (CBR) will be performed by', 'secondary analysis for ORR', 'and Endpoints', 'IRC assessment', 'based on investigator', 'assessment is added and are', 'described in Section 10.5.1,', '3']\n\n###\n\n", "completion": "END"}